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counted at a 5% annual rate. Extensive sensitivity analy-
ses were conducted. RESULTS: Over the decade of anal-
ysis, a net saving of NLG 3,050 was estimated. The cost
of galantamine makes up 5.0% of the total. The model
predicts that patients treated with galantamine are ex-
pected to spend 10.0% less time receiving home-based
FTC and 9.9% less time in a nursing home compared to
untreated patients. For every hundred patients starting
treatment on galantamine 17.8 person-years of FTC are
avoided (14.3 discounted). Secondary analyses of the ef-
fect of galantamine on behavioral symptoms estimated an
increment in total savings of NLG 4,903. Sensitivity anal-
yses run on key model parameters showed results to be
robust. CONCLUSION: On average, treatment with gal-
antamine not only provides a considerable health benefit
but is also expected to yield savings in the costs associ-
ated with mild to moderate AD in the Netherlands.
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BACKGROUND: The prevalence of Alzheimer’s disease
(AD) and vascular dementia (VD) is expected to rise sub-
stantially in the coming decades. As well, the impact of
these conditions on caregiver burden and quality of life
(QOL) is also expected to increase. OBJECTIVES: To (1)
determine how the characteristics of patients and their
caregivers affects caregiver’s QOL, and (2) identify sub-
sets of caregivers disproportionately affected by their pa-
tient’s disease. METHODS: Data were collected cross-
sectionally at baseline on 912 pairs of AD/VD patients
and their primary caregivers as part of a multinational
prospective longitudinal clinical trial. Patient and care-
giver demographics, patient CDR and DAD scores were
collected, as were caregiver EuroQol (EQ-5D) scores and
time spent on caregiving activities. Univariate and multi-
variate analyses were conducted to determine patient and
caregiver characteristics that were particularly associated
with low caregiver QOL. RESULTS: Patient severity as
measured by CDR score was moderately related to care-
giver EuroQol score (p  .05). Specifically, caregiver Eu-
roQol scores were .84, .78, .76, and .74 for questionable,
mild, moderate, and severe dementia (on the CDR), re-
spectively. In a main-effects only regression model, a
4-point and a 7-point reduction in caregiver’s EuroQol
score was associated with the caregiver being a women
and being a spouse/partner of the patient, respectively.
When an interaction term between these two variables
was introduced into the regression, the main effects of
caregiver gender and being a spouse/partner of the pa-
tient became insignificant. However, the interaction
term, being a woman spouse caring for a patient, was as-
sociated with a significant 12-point reduction in EuroQol
score. CONCLUSIONS: Worse caregiver QOL is associ-
ated with more severe patient disease stage and with be-
ing a woman caring for a demented spouse. Interventions
should thus be planned with special consideration given
this potentially more vulnerable set of caregivers.
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BACKGROUND: Optimal treatment for chronic non-
malignant pain (CNMP) is largely a function of patient
preferences in balancing pain control with treatment tol-
erability. OBJECTIVE: To estimate utilities for health
states associated with CNMP and its treatment with opi-
oids. METHODS: 96 CNMP patients (31 Canadian, 33
US, 32 Australian) completed the SF-36TM and assessed
health state descriptions and their own current health us-
ing the visual analog scale and computer-assisted adap-
tive conjoint analysis (ACA). The health state descrip-
tions included combinations of: presence/absence of 7
side effects (3 severity levels for each); pain control (5 se-
verity levels); and 2 opioid administration routes. RE-
SULTS: On average, subjects were 47 (13) years, white
(95%), female (63%), not living alone (74%), and unem-
ployed (74%). Approximately 75% of subjects in each
country were currently experiencing mild to moderate
pain; most had arthritic or low back pain. All SF-36TM
subscale scores by country were significantly lower than
US age- and gender-equivalent norms (p  0.05). Mean
utilities did not vary substantially between oral vs. trans-
dermal opioid administration. Overall, mean (SE) utili-
ties ranged from a maximum of 0.87  0.02 (no pain or
side effects) to a minimum of 0.18  0.02 (uncontrolled
pain with severe respiratory depression or severe vomit-
ing). Mean utilities for controlled pain with moderate
side effects ranged from 0.62  0.02 (mood changes,
vomiting, or respiratory depression) to 0.74  0.02
(sweating). Uncontrolled pain without side effects (0.64 
0.02) was preferred to well-controlled pain with severe
side effects (range: 0.41  0.03 [mood changes, vomit-
ing, or respiratory depression] to 0.54  0.03 [sweat-
ing]). CONCLUSIONS: Results indicate a patient prefer-
ence for opioid therapy that causes fewer side effects.
Although pain may be extremely debilitating, tolerating
pain to avoid opioid side effects may be preferable to
controlling pain and experiencing certain opioid side ef-
fects. Opioid side effects combined with poorly-con-
trolled pain may result in very low health utility.
